glp-1 and kidney receptor agonists next-generation metabolic hormone therapies in chronic disease Potential renoprotective effects of GLP1

Helping patients establish realistic expectations and providing education about how the medication works are important to help ensure desired outcomes

[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Chuong V., Farokhnia M., Khom S., Pince C.L., Elvig S.K., Vlkolinsky R., Marchette R.C., Koob G.F., Roberto M., Vendruscolo L.F., et al

The Therapeutic Goods Administration, an arm of the Australian government, said the Trulicity shortage is expected to continue until June 30, 2026

however, no significant differences in eGFR decline were identified in any of the treatment groups [44]

This may also increase long-term health risks